Technical Analysis for PGNX - Progenics Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade C 4.91 1.45% 0.07
PGNX closed up 1.45 percent on Friday, January 18, 2019, on 51 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical PGNX trend table...

Date Alert Name Type % Chg
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 17 Wide Bands Range Expansion 1.45%
Jan 17 Overbought Stochastic Strength 1.45%
Jan 16 Wide Bands Range Expansion 0.41%
Jan 16 Overbought Stochastic Strength 0.41%
Jan 15 Stochastic Sell Signal Bearish 2.72%
Jan 15 Crossed Above 50 DMA Bullish 2.72%
Jan 15 MACD Bullish Centerline Cross Bullish 2.72%
Jan 15 180 Bullish Setup Bullish Swing Setup 2.72%

Older signals for PGNX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Progenics Pharmaceuticals, Inc. engages in the research and development of biotechnology product candidates in the areas of oncology and therapeutics worldwide. The company offers RELISTOR (methylnaltrexone bromide), a subcutaneous injection for the treatment of opioid induced constipation (OIC) in patients with advanced illnesses, such as cancer, as well as for the treatment of OIC in patients with non-cancer pain; and RELISTOR-Oral, which has completed Phase III testing for the treatment of OIC in patients with non-cancer pain. It also provides oncology medicines, including PSMA ADC that is in Phase II testing for treatment of prostate and other cancers; and MIP-1404, which is in Phase II testing for imaging agent for prostate cancer; and Azedra for the treatment of pheochromocytoma and paraganglioma, and Neuroblastoma. PSMA ADC is an antibody-drug conjugate (ADC) that targets prostate specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells, as well as on the neovasculature of various other types of solid tumors. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of RELISTOR worldwide other than Japan. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in Tarrytown, New York.
Is PGNX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 9.42
52 Week Low 3.62
Average Volume 1,360,172
200-Day Moving Average 6.6597
50-Day Moving Average 4.7553
20-Day Moving Average 4.3975
10-Day Moving Average 4.77
Average True Range 0.2689
ADX 20.05
+DI 26.0015
-DI 16.2932
Chandelier Exit (Long, 3 ATRs ) 4.1733
Chandelier Exit (Short, 3 ATRs ) 4.4267
Upper Bollinger Band 5.2149
Lower Bollinger Band 3.5801
Percent B (%b) 0.81
BandWidth 37.175668
MACD Line 0.0718
MACD Signal Line -0.0175
MACD Histogram 0.0893
Fundamentals Value
Market Cap 345.02 Million
Num Shares 70.3 Million
EPS -0.06
Price-to-Earnings (P/E) Ratio -81.83
Price-to-Sales 6.47
Price-to-Book 5.52
PEG Ratio -0.02
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.21
Resistance 3 (R3) 5.20 5.09 5.16
Resistance 2 (R2) 5.09 5.01 5.10 5.14
Resistance 1 (R1) 5.00 4.97 5.05 5.01 5.13
Pivot Point 4.89 4.89 4.91 4.90 4.89
Support 1 (S1) 4.80 4.81 4.85 4.81 4.69
Support 2 (S2) 4.69 4.77 4.70 4.68
Support 3 (S3) 4.60 4.69 4.66
Support 4 (S4) 4.61